On November 30, 2022, the Company announced the commencement of a strategic review process that considered a full range of strategic alternatives including corporate sale, merger or other business combination, a sale of all or a portion of the Company’s assets, strategic investment or other significant transaction. (TSX: TMD), a medical device company headquartered in Toronto, Ontario with operations in Chapel Hill, North Carolina, was focused on enhancing robotic assisted surgery (RAS) using innovative technology through a single access point. The MCTO does not affect the ability of shareholders who are not named in the MCTO to trade their securities. The MCTO restricts all trading in and all acquisitions of the securities of the Company, directly or indirectly, by the Chief Executive Officer and the Chief Financial Officer of the Company until two full business days following the receipt by the OSC of the Annual Filing Documents and any other filings the Company is required to make under Ontario securities laws, including the Q1 Filings, or upon the further order of the director of the OSC. The MCTO was granted by the OSC on April 3, 2023. On March 22, 2023, and as further updated on April 3, 2023, April 17, 2023, and May 15, 2023, the Company announced (the “ Default Announcement”) that under National Policy 12-203 Management Cease Trade Orders it had applied to the Ontario Securities Commission (the “ OSC”) requesting a management cease trade order (“ MCTO”) be imposed in respect of the late filing of the Annual Filing Documents.
As announced on May 15, 2023, the Company expects to file the Annual Filing Documents by May 31, 2023. (“ Titan” or the “ Company”) (TSX: TMD OTC: TMDIF) today announces that, as a result of a delay in filing its annual financial statements, the related management’s discussion and analysis and annual information form, and the accompanying chief executive officer and chief financial officer certification for its financial year ended Decem(collectively, the “ Annual Filing Documents”), the Company will also be delayed in the filing of its financial statements, the related management’s discussion and analysis and the accompanying chief executive officer and chief financial officer certification for its first quarter ended Ma(the “ Q1 Filing Documents”) and now expects to file the Q1 Filing Documents by June 9, 2023. TORONTO, Ontario, (GLOBE NEWSWIRE) - Titan Medical Inc.
0 kommentar(er)
